AFTD Medical Advisory Council member Murray Grossman, M.D., Ed.D., helps The Boston Globe answer the question: “What is frontotemporal dementia, and is it inheritable?” Dr. Grossman is Director of the Penn Frontotemporal Degeneration Center and a University of Pennsylvania professor. Click here to read the article.
In this blog, Dan Browning, who writes about health care and medical research for the Star Tribune in Minneapolis, describes the aftermath of his wife’s recent death from complications related to FTD. Click here to read the full article.
Researchers have shown that loss of cells in the retina is one of the earliest signs of FTD in people with a genetic risk. Click here to read the full article.
The Pierce family held their annual golf outing and auction on July 25th. Among the prizes to be won was one-on-one time with the Heisman Trophy. Click here to read the article.
Frontotemporal degeneration (FTD), a disease process that results in progressive damage to the temporal and/or frontal lobes of the brain, has been formally included in national research priorities to cure Alzheimer’s disease and other dementias by 2025, the Association of Frontotemporal Degeneration (AFTD) announced today. The update to the NAPA plan also coincided with AFTD’s release of a comprehensive research white paper, FTD Research and Drug Development Landscape Analysis. For the full press release, click here.